Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
ADAPYAdaptimmune Therapeutics PLC
| Figure | ADAPYAdaptimmune Therapeutics PLCFY2024 · Dec |
|---|---|
| Revenue | $178.03M |
| Revenue, yoy | +195.3% |
| Net income | $70.81M |
| Net income, yoy | +37.8% |
| Net margin | -39.8% |
| Free cash flow | $74.09M |
| FCF margin | -41.6% |
| EPS, diluted | $0.05 |
Add another company.
Annual · FY2020–FY2024 · USD
From SEC EDGARSame fiscal periods, as filed